Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Malte Lenders

Showing results (11-20 of 62) with videos related to

Pageof 7
Sort By:
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 29, 2024
Biochemical Amenability in Fabry Patients Under Chaperone Therapy-How and When to Test?Malte Lenders, Elise Raphaela Menke, Eva Brand
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 1, 2025
Progress and Challenges in the Treatment of Fabry DiseaseMalte Lenders, Elise Raphaela Menke, Eva Brand
Molecular Genetics and Metabolism|September 5, 2020
Detailed epitope mapping of neutralizing anti-drug antibodies against recombinant α-galactosidase A in patients with Fabry diseaseDavid Scharnetzki, Franciska Stappers, Malte Lenders, et al.
Molecular Therapy. Methods & Clinical Development|August 22, 2022
Pre-existing anti-drug antibodies in Fabry disease show less affinity for pegunigalsidase alfaMalte Lenders, Solvey Pollmann, Melina Terlinden, et al.
Orphanet Journal of Rare Diseases|October 1, 2018
Neutralizing anti-drug antibodies in Fabry disease have no obvious clinical impact?Malte Lenders, Boris Schmitz, Stefan-Martin Brand, et al.
Frontiers in Immunology|December 17, 2021
Endothelial Dysfunction in Fabry Disease Is Related to Glycocalyx DegradationSolvey Pollmann, David Scharnetzki, Dominique Manikowski, et al.
Frontiers in Immunology|January 29, 2026
A rapid method to reduce drug interferences for antibody measurements in pegunigalsidase alfa-treated patients with Fabry diseaseMalte Lenders, Elisa Rudolph, Michael Rudnicki, et al.
Frontiers in Immunology|October 11, 2023
Characterization of pre-existing anti-PEG and anti-AGAL antibodies towards PRX-102 in patients with Fabry diseaseMalte Lenders, Lina Marleen Feidicker, Stefan-Martin Brand, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 30, 2024
Relevance of Neutralizing Antibodies for the Pharmacokinetics of Pegunigalsidase Alfa in Patients with Fabry DiseaseMalte Lenders, Elise Raphaela Menke, Michael Rudnicki, et al.
International Journal of Molecular Sciences|June 26, 2026
Identification of Potential Proteins Interacting with α-Galactosidase A to Analyze the Pathogenesis of Fabry DiseaseElise Raphaela Menke, Jürgen Eirich, Iris Finkemeier, et al.
Pageof 7

Showing results (11-20 of 62) with videos related to

Sort By:
Pageof 7
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 29, 2024
Biochemical Amenability in Fabry Patients Under Chaperone Therapy-How and When to Test?Malte Lenders, Elise Raphaela Menke, Eva Brand
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 1, 2025
Progress and Challenges in the Treatment of Fabry DiseaseMalte Lenders, Elise Raphaela Menke, Eva Brand
Molecular Genetics and Metabolism|September 5, 2020
Detailed epitope mapping of neutralizing anti-drug antibodies against recombinant α-galactosidase A in patients with Fabry diseaseDavid Scharnetzki, Franciska Stappers, Malte Lenders, et al.
Molecular Therapy. Methods & Clinical Development|August 22, 2022
Pre-existing anti-drug antibodies in Fabry disease show less affinity for pegunigalsidase alfaMalte Lenders, Solvey Pollmann, Melina Terlinden, et al.
Orphanet Journal of Rare Diseases|October 1, 2018
Neutralizing anti-drug antibodies in Fabry disease have no obvious clinical impact?Malte Lenders, Boris Schmitz, Stefan-Martin Brand, et al.
Frontiers in Immunology|December 17, 2021
Endothelial Dysfunction in Fabry Disease Is Related to Glycocalyx DegradationSolvey Pollmann, David Scharnetzki, Dominique Manikowski, et al.
Frontiers in Immunology|January 29, 2026
A rapid method to reduce drug interferences for antibody measurements in pegunigalsidase alfa-treated patients with Fabry diseaseMalte Lenders, Elisa Rudolph, Michael Rudnicki, et al.
Frontiers in Immunology|October 11, 2023
Characterization of pre-existing anti-PEG and anti-AGAL antibodies towards PRX-102 in patients with Fabry diseaseMalte Lenders, Lina Marleen Feidicker, Stefan-Martin Brand, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 30, 2024
Relevance of Neutralizing Antibodies for the Pharmacokinetics of Pegunigalsidase Alfa in Patients with Fabry DiseaseMalte Lenders, Elise Raphaela Menke, Michael Rudnicki, et al.
International Journal of Molecular Sciences|June 26, 2026
Identification of Potential Proteins Interacting with α-Galactosidase A to Analyze the Pathogenesis of Fabry DiseaseElise Raphaela Menke, Jürgen Eirich, Iris Finkemeier, et al.
Pageof 7